Cancer Biotech Elicio Finds Path to Public Markets Via Angion Reverse Merger

MED CITY NEWS: Elicio Therapeutics dipped its toe in the IPO waters but decided to go public by merging with publicly traded Angion Biomedica. Clinical-stage Elicio is developing immunotherapies, including cancer vaccines, that work by targeting immune cells located in the lymph nodes.